CHAM
MACK

Clear Harbor Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Clear Harbor Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,094
Closed -$195K – 267
2017
Q2 		$195K Buy
18,094
+16,264
+889% +$332K 0.04% 232
2017
Q1 		$44K Sell
1,830
-305
-14% -$7.63K 0.01% 245
2016
Q4 		$69K Sell
2,135
-26
-1% -$1.11K 0.01% 240
2016
Q3 		$108K Sell
2,161
-165
-7% -$6.85K 0.02% 232
2016
Q2 		$99K Sell
2,326
-38
-2% -$2.07K 0.02% 242
2016
Q1 		$156K Sell
2,364
-6
-0.3% -$313 0.03% 224
2015
Q4 		$147K Sell
2,370
-255
-10% -$17.9K 0.03% 235
2015
Q3 		$176K Buy
2,625
+32
+1% +$2.61K 0.04% 239
2015
Q2 		$252K Hold
2,593
– – 0.05% 240
2015
Q1 		$242K Hold
2,593
– – 0.05% 241
2014
Q4 		$231K Sell
2,593
-38
-1% -$2.77K 0.05% 245
2014
Q3 		$182K Buy
2,631
+89
+4% +$4.76K 0.04% 197
2014
Q2 		$146K Buy
+2,542
New +$129K 0.03% 203

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Clear Harbor Asset Management's MACK Position: Q3 2017 in Review

Clear Harbor Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 18,094 shares — an estimated $195K sold.

Clear Harbor Asset Management first reported a position in MACK in Q2 2014 and held it in 13 quarters. The position peaked at $252K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Clear Harbor Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Clear Harbor Asset Management sold 18,094 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $195K.
  • Clear Harbor Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 13 quarters.
  • Clear Harbor Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $252K in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Clear Harbor Asset Management's 13F filing for Q3 2017, filed 25 Oct 2017.